Cargando…
Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer
BACKGROUND: Differentiating malignant lung tumors from benign pulmonary nodules is a great challenge. While the analysis of bronchoalveolar lavage fluid (BALF) is used for diagnosing infections and interstitial lung diseases, there is limited evidence to support its use for lung cancer diagnosis. Th...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339831/ https://www.ncbi.nlm.nih.gov/pubmed/34422992 http://dx.doi.org/10.21037/atm-21-2579 |
_version_ | 1783733676601769984 |
---|---|
author | Zeng, Daxiong Wang, Cangguo Mu, Chuanyong Su, Meiqin Mao, Jingyu Huang, Jianan Xu, Jiayue Shao, Lin Li, Bing Li, Haiyan Li, Bingsi Zhao, Jun Jiang, Junhong |
author_facet | Zeng, Daxiong Wang, Cangguo Mu, Chuanyong Su, Meiqin Mao, Jingyu Huang, Jianan Xu, Jiayue Shao, Lin Li, Bing Li, Haiyan Li, Bingsi Zhao, Jun Jiang, Junhong |
author_sort | Zeng, Daxiong |
collection | PubMed |
description | BACKGROUND: Differentiating malignant lung tumors from benign pulmonary nodules is a great challenge. While the analysis of bronchoalveolar lavage fluid (BALF) is used for diagnosing infections and interstitial lung diseases, there is limited evidence to support its use for lung cancer diagnosis. This study aimed to interrogate the potential of using BALF cell-free DNA (cfDNA) to discriminate malignant lesions from benign nodules. METHODS: Fifty-three patients with solid pulmonary nodules (≤2 cm) were prospectively enrolled, including 21 confirmed with benign disease and 32 with malignant tumors. Mutations were profiled for 30 tumor tissues and 40 BALFs. Paired BALFs and plasma from 48 patients underwent DNA methylation profiling. A methylome-based classification model was developed for BALF and plasma separately. RESULTS: Among the 30 patients with paired tissues and BALFs, 96.7% and 70% had alterations detected from their tissues (79 alterations) and BALFs (53 alterations), respectively. Using tissues as references, BALFs revealed 14 new alterations and missed 41. BALF mutation displayed a sensitivity of 71%, specificity of 77.8%, and accuracy of 72.5% in detecting lung cancer. BALF methylation achieved an accuracy of 81.3%, with both sensitivity and specificity being 81%. Plasma methylation showed a 66.7% sensitivity, 71.4% specificity, and 68.8% accuracy. BALF methylation also demonstrated 82.4% sensitivity in stage I patients. Parallel bronchoscopy, lavage cytology, and bronchial brushing demonstrated an inferior sensitivity of 23%, 3.1%, and 9.7%, respectively, compared with BALF methylation and mutation (P<0.0001). CONCLUSIONS: BALF cfDNA can serve as a liquid biopsy media for both mutation and methylation profiling, demonstrating better sensitivities in distinguishing small malignant tumors from benign nodules than conventional methods. KEYWORDS: Lung cancer diagnosis; pulmonary nodule; bronchoalveolar lavage fluid (BALF); methylation; genomic mutation |
format | Online Article Text |
id | pubmed-8339831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-83398312021-08-20 Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer Zeng, Daxiong Wang, Cangguo Mu, Chuanyong Su, Meiqin Mao, Jingyu Huang, Jianan Xu, Jiayue Shao, Lin Li, Bing Li, Haiyan Li, Bingsi Zhao, Jun Jiang, Junhong Ann Transl Med Original Article BACKGROUND: Differentiating malignant lung tumors from benign pulmonary nodules is a great challenge. While the analysis of bronchoalveolar lavage fluid (BALF) is used for diagnosing infections and interstitial lung diseases, there is limited evidence to support its use for lung cancer diagnosis. This study aimed to interrogate the potential of using BALF cell-free DNA (cfDNA) to discriminate malignant lesions from benign nodules. METHODS: Fifty-three patients with solid pulmonary nodules (≤2 cm) were prospectively enrolled, including 21 confirmed with benign disease and 32 with malignant tumors. Mutations were profiled for 30 tumor tissues and 40 BALFs. Paired BALFs and plasma from 48 patients underwent DNA methylation profiling. A methylome-based classification model was developed for BALF and plasma separately. RESULTS: Among the 30 patients with paired tissues and BALFs, 96.7% and 70% had alterations detected from their tissues (79 alterations) and BALFs (53 alterations), respectively. Using tissues as references, BALFs revealed 14 new alterations and missed 41. BALF mutation displayed a sensitivity of 71%, specificity of 77.8%, and accuracy of 72.5% in detecting lung cancer. BALF methylation achieved an accuracy of 81.3%, with both sensitivity and specificity being 81%. Plasma methylation showed a 66.7% sensitivity, 71.4% specificity, and 68.8% accuracy. BALF methylation also demonstrated 82.4% sensitivity in stage I patients. Parallel bronchoscopy, lavage cytology, and bronchial brushing demonstrated an inferior sensitivity of 23%, 3.1%, and 9.7%, respectively, compared with BALF methylation and mutation (P<0.0001). CONCLUSIONS: BALF cfDNA can serve as a liquid biopsy media for both mutation and methylation profiling, demonstrating better sensitivities in distinguishing small malignant tumors from benign nodules than conventional methods. KEYWORDS: Lung cancer diagnosis; pulmonary nodule; bronchoalveolar lavage fluid (BALF); methylation; genomic mutation AME Publishing Company 2021-07 /pmc/articles/PMC8339831/ /pubmed/34422992 http://dx.doi.org/10.21037/atm-21-2579 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Zeng, Daxiong Wang, Cangguo Mu, Chuanyong Su, Meiqin Mao, Jingyu Huang, Jianan Xu, Jiayue Shao, Lin Li, Bing Li, Haiyan Li, Bingsi Zhao, Jun Jiang, Junhong Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer |
title | Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer |
title_full | Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer |
title_fullStr | Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer |
title_full_unstemmed | Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer |
title_short | Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer |
title_sort | cell-free dna from bronchoalveolar lavage fluid (balf): a new liquid biopsy medium for identifying lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339831/ https://www.ncbi.nlm.nih.gov/pubmed/34422992 http://dx.doi.org/10.21037/atm-21-2579 |
work_keys_str_mv | AT zengdaxiong cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer AT wangcangguo cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer AT muchuanyong cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer AT sumeiqin cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer AT maojingyu cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer AT huangjianan cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer AT xujiayue cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer AT shaolin cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer AT libing cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer AT lihaiyan cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer AT libingsi cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer AT zhaojun cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer AT jiangjunhong cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer |